Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLUTION: 177Lu-PSMA +/- Ipilimumab and Nivolumab in mCRPC
NCT05150236Phase 2Active, not recruiting
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Apr 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by ANZUP Cancer Trials Group. Started Apr 2022; status: active, not recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05150236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150236.